logo
Plus   Neg
Share
Email

Novartis:FDA Approves Lutathera For Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG (NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application or NDA for Lutathera for treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.

Lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications) — a somatostatin analog peptide designed to target tumors with radiolabeled molecules that bind to specific receptors expressed by the tumor — is the first radiopharmaceutical approved for the treatment of gastroenteropancreatic neuroendocrine tumors.

Lutathera, which received orphan drug designation from the FDA, is a first-in-
class drug and the first available FDA-approved Peptide Receptor Radionuclide
Therapy (PRRT), a form of treatment comprising of a targeting molecule that
carries a radioactive component.

The approval was based on a Phase 3 study which demonstrated a 79% reduction in the risk of disease progression or death within the Lutathera plus best standard of care arm (octreotide LAR 30mg every four weeks) compared to 60 mg of octreotide LAR alone (hazard ratio 0.21, 95% CI; 0.13-0.32; p<00.001).

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Hundreds of Google employees signed a petition protesting the company's secret project to develop a censored version of its search engine for China. In a letter, posted by Buzzfeed and first reported by the New York Times, the employees said that work on the project and Google's return to China raises "urgent moral and ethical issues." Google is trying to keep a foothold in China. U.S. President Donald Trump has expressed support for a possible end to quarterly earnings reports for publicly traded companies, saying it would allow greater flexibility and save money. Nvidia Corp. (NVDA) Thursday reported a surge in its second-quarter profit, driven largely by a better-than-expected growth in revenues and strong margins. However, shares of the graphics chip maker slipped about 4 percent in extended session, as its revenue outlook for the current quarter fell short...
Follow RTT